Researchers manufacture the SARS-CoV-2 RBD in pichia
Researchers in the United States and India have developed a high-volume, low-cost platform for manufacturing vaccines to protect against different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The approach produces the receptor-binding domain (RBD) of the spike protein that the virus uses to bind to and infect host cells. The spike RBD is a primary target of neutralizing antibodies following vaccination or natural infection.
The new manufacturing process uses a genetically engineered strain of the microbe
Komagataella phaffii (Pichia pastoris) to produce the spike RBD. The use of this microbial host eliminates the need for methanol-induction of the recombinant RBD gene, which can present challenges in large-scale facilities.
Insights on the Meningococcal Vaccine Global Market to 2026 - Featuring GlaxoSmithKline, Pfizer and Sanofi Among Others prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Bombay High Court Rejects Plea To Restrain Serum Institute Of India From Using COVISHIELD Trademark
Share This -
x
The Bombay High Court on Tuesday refused to grant interim relief to pharmaceutical company Cutis Biotech and restrain Serum Institute of India (SII) from using the trademark Covishield, for its coronavirus vaccine.
A division bench of
Justices Nitin Jamdar and C. V. Bhadang said that the Nanded civil court s order, refusing Cutis an injunction against Serum Institute was not arbitrary or perverse warranting the HC s intervention.
The bench added that restraining SII from temporarily using the trademark would have
large-scale ramifications
Insights on the Meningococcal Vaccine Global Market to 2026 - Featuring GlaxoSmithKline, Pfizer and Sanofi Among Others prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Synopsis
True North’s part exit from PolicyBazaar comes at a time when the insurance aggregator is lining up an initial public offering (IPO) for some time this year.
ETtech Policybazaar is seeking a listing before the end of this year. (Illustration: Rahul Awasthi/ETtech)
Mumbai:True North has made a part exit from PolicyBazaar. The homegrown private equity fund had invested about $50 million in the insurance aggregator in 2017 and had sold a part stake in October 2020.
The move comes ahead of the
PolicyBazaar IPO planned for some time this year.
True North has sold its stake to five independent buyers Ashoka India Equity Investment Trust Plc, Triumph Global Holdings Pte Ltd., Serum Institute of India Pvt. Ltd., IIFL Special Opportunities Fund Series 8 and India Acorn Fund Ltd.